Zydus Cadila has received final approval from the US health regulator to market anti-diuretic Desmopressin nasal spray solution in the American market.
The drug firm has received final approval from the United States Food and Drug Administration (USFDA) to market Desmopressin nasal spray solution USP, 10 mcg/0.1 mL per spray, 5 ml bottle, Zydus Cadila said in a statement today.
The product will be manufactured at the group’s formulations manufacturing facility at Moraiya in Ahmedabad, it added.
The nasal spray is indicated as an anti-diuretic replacement therapy in the management of central diabetes insipidus, excessive urination and drinking excessive amount of fluids following head trauma or surgery in the pituitary region and nocturia, Zydus Cadila said.
The group now has more than 160 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process by the company.
Shares of Cadila Healthcare, the listed entity of the group, closed 3.88 per cent higher at Rs 492.80 on the BSE today.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.